Skip to main content
Fig. 3 | Parasites & Vectors

Fig. 3

From: The therapeutic effect of larval saliva and hemolymph of Lucilia sericata on the treatment of Leishmania major lesion in BALB/c mice946

Fig. 3

Dose-response curves regarding the effect of Lucilia sericata larval-derived products on Leishmania major promastigotes (IC50) using MTT assay. a Larval saliva IC50 vs. larval hemolymph IC50 at 24 h. b Larval saliva IC50 vs. larval hemolymph IC50 at 48 h. c Larval saliva IC50 vs. larval hemolymph IC50 at 72 h. d Larval saliva IC50 vs. larval hemolymph IC50 at 96 h and compared with standard treatment (glucantime)

Back to article page